Manhattan Isotope Technology, with the support of molecular imaging developer Positron, has signed a memorandum of understanding with the ARRONAX cyclotron facility in Nantes, France, that will allow the firms to collaborate on the production of strontium-82 (Sr-82) and other medical radionuclides, Positron said.
Positron expects Sr-82 validation samples to begin arriving from ARRONAX (Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic) to Manhattan Isotope's Lubbock, TX, processing facility in early 2012, with the filing of a drug master file with the U.S. Food and Drug Administration (FDA) in the spring. Currently, the only supplier of active pharmaceutical ingredient (API)-grade strontium-82 in the U.S. is the U.S. Department of Energy, Positron said.
Earlier this month, Positron moved to acquire Manhattan Isotope Technology; the deal is scheduled to close on January 2, 2012, after final transaction documents are executed.
